Sunrest Lifescience Ltd
Pharmaceuticals & Biotechnology | Small Cap
Sunrest Lifescience Ltd demonstrates a mixed financial performance. The company shows strengths in profitability, driven by strong gross, operating, and net profit margins. Its coverage ratios are adequate, particularly regarding interest obligations. However, the company faces challenges in liquidity, growth, and efficiency, indicating potential difficulties in meeting short-term obligations and leveraging assets effectively. Financial ratios are also weak, suggesting limited earnings and book value per share. While the company's profitability and coverage offer some stability, addressing the weaknesses in liquidity, growth, efficiency, and financial metrics is crucial for sustained financial health and future success. The healthcare industry's dynamics, including regulatory changes and competitive pressures, could further impact the company's performance.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsHighly Undervalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio2.00
- Financial Ratio3.60
- Profitability Ratio5.60
- Efficiency Ratio4.67
- Coverage Ratio5.60
- Solvency Ratio8.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayBearish
- 1 WeekBearish
- 1 MonthBearish
Sunrest Lifescience Ltd demonstrates a mixed financial performance. The company shows strengths in profitability, driven by strong gross, operating, and net profit margins. Its coverage ratios are adequate, particularly regarding interest obligations. However, the company faces challenges in liquidity, growth, and efficiency, indicating potential difficulties in meeting short-term obligations and leveraging assets effectively. Financial ratios are also weak, suggesting limited earnings and book value per share. While the company's profitability and coverage offer some stability, addressing the weaknesses in liquidity, growth, efficiency, and financial metrics is crucial for sustained financial health and future success. The healthcare industry's dynamics, including regulatory changes and competitive pressures, could further impact the company's performance.
Overall Valuation Score
P/E RATIO (TTM)
9.42
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
7.06
P/B RATIO
1.42
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
0.39
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.02
EV/EBITDA RATIO
2.88
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹33.9 as on Jun 21, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company's growth ratios are weak, indicating limited expansion in revenue, operating profit, earnings per share, assets, and net income. This raises concerns about the company's ability to capitalize on market opportunities and sustain long-term growth. Without significant growth, the company may struggle to attract investors and maintain its competitive position in the market. Strategic initiatives are needed to stimulate growth across various financial metrics.
| Growth Ratios | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue Growth Rate | 112 | |
| Operating Profit Growth Rate | 236.96 | |
| Earnings Per Share (EPS) Growth | 105.13 | |
| Asset Growth Rate | 21.76 | |
| Net Income Growth Rate | 296.04 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios indicate mixed performance. While capital expenditures are well-managed, the adjusted and cash earnings per share, book value per share, and dividend per share are low. Managing capital expenditures helps control costs, but the low earnings and book value per share raise concerns about profitability and shareholder value. Improving these metrics is essential for enhancing overall financial health and attracting investors.
| Financial Ratios | Mar 2025 | Mar 2026 |
|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 4.7 | 27.91 |
| Cash Earnings Per Share (Cash EPS) | 4.93 | 21.37 |
| Book Value Per Share | 37.93 | 47.51 |
| Dividend Per Share (DPS) | 0 | 0 |
| Capital Expenditures (CapEx) | 1.2 | 2.7 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability ratios are strong, driven by high gross, operating, and net profit margins. These favorable margins indicate efficient cost management and effective pricing strategies. Strong profitability is a key strength, providing the company with financial stability and the ability to reinvest in growth opportunities. However, returns on capital employed, equity and assets are low.
| Profitability Ratios | Mar 2025 | Mar 2026 |
|---|---|---|
| Gross Profit Margin | 8.77 | 12.73 |
| Return on Capital Employed (ROCE) | 13.29 | 28.55 |
| Return on Equity (ROE) | 12.39 | 39.16 |
| Return on Assets (ROA) | 5.17 | 14.3 |
| Operating Margin | 9.07 | 14.41 |
| Net Margin | 6.05 | 11.29 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency in asset utilization is mixed. While days sales in inventory and receivable days are favorable, indicating efficient inventory and receivables management, the fixed asset and capital turnover ratios are weak, suggesting underutilization of assets to generate revenue. Efficient inventory and receivables management helps optimize working capital, while improving asset turnover is essential for enhancing overall operational efficiency and profitability.
| Efficiency Ratios | Mar 2025 | Mar 2026 |
|---|---|---|
| Fixed Asset Turnover Ratio | 7.66 | 8.28 |
| Inventory Turnover Ratio | 3.17 | 4.63 |
| Receivables Turnover Ratio | 0.92 | 2.06 |
| Days Sales in Inventory Ratio | 115.14 | 78.83 |
| Receivable Days | 397.34 | 177.18 |
| Capital Turnover Ratio | 1.52 | 2.19 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company shows a good capacity to cover its interest obligations, but dividend coverage is weak. The favorable interest coverage ratio offers financial stability, ensuring the company can comfortably meet its debt obligations. However, the limited equity dividend coverage raises concerns about the ability to consistently reward shareholders. Balancing debt obligations and shareholder returns is crucial for maintaining investor confidence and financial health.
| Coverage Ratios | Mar 2025 | Mar 2026 |
|---|---|---|
| Interest Coverage Ratio | 9.45 | 8.12 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's solvency position presents a mixed picture. While debt ratios are favorable, suggesting lower financial leverage, the equity ratio is weak, indicating a smaller proportion of assets financed by equity. A lower debt burden provides financial flexibility, but a thin equity base may increase vulnerability to market fluctuations and economic downturns. Balancing debt and equity is crucial for long-term financial stability.
| Solvency Ratios | Mar 2025 | Mar 2026 |
|---|---|---|
| Debt Ratio | 0.26 | 0.37 |
| Debt to Equity Ratio | 0.35 | 0.59 |
| Equity Ratio | 0.74 | 0.63 |
| Debt To Asset Ratio | 0.1 | 0.17 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is weak, indicating potential difficulties in meeting its short-term obligations. The low current, quick, and cash ratios suggest insufficient liquid assets to cover current liabilities. While a conservative approach to liquidity can sometimes be justified, the consistent lack of liquid assets raises concerns about the company's ability to handle unexpected expenses or take advantage of immediate investment opportunities. This may affect its operational flexibility and increase financial risk.
| Liquidity Ratios | Mar 2025 | Mar 2026 |
|---|---|---|
| Current Ratio | 1.48 | 1.61 |
| Quick Ratio | 1.22 | 1.17 |
| Cash Ratio | 0.05 | 0.07 |
| Operating Cash Flow Ratio | 0.08 | 0 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Sunrest Lifescience Ltd | 4.17 | 7.06 | Highly Undervalued | 10.21 | 3.60 | 8.00 |
| 2 | Ortin Global Ltd | 3.45 | -19.80 | Neutral | -0.72 | -0.91 | -0.74 |
The management effectiveness of Sunrest Lifescience Ltd is mixed. While the company demonstrates a reasonable Operating Profit Margin (OPM) of 9.07%, indicating operational efficiency, there are concerns regarding growth and returns due to the absence of compounded sales growth and profit growth data. The ROCE is 6.34%, and the ROE is 2.61%, both quite low. The lack of dividend payouts and recent sales and profit data necessitates a cautious assessment.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Operating Profit Margin | 9.07% | Indicates operational efficiency |
| CONS | Return on Capital Employed | 6.34% | Low return on capital employed |
| Return on Equity | 2.61% | Low return on equity |
Financial Performance & Growth
Sunrest Lifescience Ltd's financial growth shows a mixed performance. The OPM is 9.07%. The absence of data for Compounded Sales Growth and Compounded Profit Growth makes assessing the sustainability of revenue and profit expansion difficult. The recent sales and profit data are also missing, complicating the evaluation of the company's financial trajectory. This lack of data raises concerns about the consistency of the company's financial performance.
Capital Efficiency & Returns
The capital efficiency and returns for Sunrest Lifescience Ltd are weak. The current ROCE is 6.34%, and ROE is 2.61%. The absence of historical ROCE and ROE data prevents a thorough evaluation of trends in generating returns from capital employed and shareholder funds. Without these metrics, it is challenging to determine how effectively the company has been utilizing its resources over time.
Financial Health & Prudence
The financial health and prudence of Sunrest Lifescience Ltd present a mixed view. While there is an interest expense of ₹0.31, the absence of debt/equity ratio and borrowings data makes it challenging to evaluate the degree of leverage and associated risks. The interest coverage ratio cannot be assessed due to the lack of operating profit data. The company does not have any dividend payout, as the Dividend Payout % is 0.00%, which may concern investors seeking regular income. The absence of enterprise value (EV) data relative to market cap and debt further limits the ability to assess if the company's valuation is justified.
Shareholding & Ownership Structure
The shareholding and ownership structure of Sunrest Lifescience Ltd appears stable. Promoters maintain a consistent holding of 69.91% from March 2024 to March 2025. This indicates an alignment of interest between the management and the shareholders. The public holding remains constant, at 30.09% during the same period. The number of shareholders has decreased from 580 in March 2024 to 459 in March 2025, which may point to consolidation among investors. The absence of FII and DII holdings data limits a complete understanding of institutional investor confidence. Overall, the consistent promoter holding suggests stability in the company's ownership structure.
The risk assessment for Sunrest Lifescience Ltd indicates moderate risk. There are limited data points to comprehensively evaluate several risk factors. The absence of information on off-balance sheet exposures and contingent liabilities prevents a complete assessment of potential financial vulnerabilities. The lack of segment performance volatility data makes it difficult to assess the consistency of revenue streams. The absence of foreign exchange or interest rate exposure data and regulatory compliance cost trends further limits the risk assessment. Given these limitations, a cautious approach is warranted.
Off-balance sheet exposure quantification
There is no specific data available on off-balance sheet exposure quantification, making it impossible to assess this risk factor.
Contingent liability evaluation
There is no specific data available on contingent liability evaluation, making it impossible to assess this risk factor.
Segment performance volatility
There is no specific data available on segment performance volatility, making it impossible to assess this risk factor.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1033.39Bullish
- SMA 2033.32Bullish
- SMA 5034.66Bearish
- EMA 1033.53Bullish
- EMA 2033.60Bullish
- EMA 5034.43Bearish
- DEMA 1033.69Bullish
- DEMA 2033.17Bullish
- DEMA 5033.15Bullish
- TEMA 1034.00Bearish
- TEMA 2033.47Bullish
- TEMA 5032.88Bullish
- MACD-0.25Bullish
- ADX28.70Strong Trend
- IndicatorValueSignal
- RSI52.45Neutral
- CCI75.90Neutral
- ROC 92.42Bullish
- ROC 141.19Bullish
- ROC 25-0.29Bearish
- Stoch K97.22Overbought
- Stoch D90.94Overbought
- IndicatorValueSignal
- BB Upper34.58Neutral
- BB Middle33.32Neutral
- BB Lower32.07Neutral
- ATR0.20Low Volatility
- IndicatorValueSignal
- MFI37.95Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1033.18Bullish
- SMA 2033.83Bullish
- SMA 5035.63Bearish
- EMA 1033.57Bullish
- EMA 2033.95Bearish
- EMA 5035.16Bearish
- DEMA 1033.42Bullish
- DEMA 2033.08Bullish
- DEMA 5033.43Bullish
- TEMA 1033.76Bullish
- TEMA 2033.10Bullish
- TEMA 50N/AN/A
- MACD-0.60Bullish
- ADX22.12Weak Trend
- IndicatorValueSignal
- RSI45.94Neutral
- CCI3.80Neutral
- ROC 91.19Bullish
- ROC 14-0.29Bearish
- ROC 25-3.14Bearish
- Stoch K94.59Overbought
- Stoch D76.98Neutral
- IndicatorValueSignal
- BB Upper35.82Neutral
- BB Middle33.83Neutral
- BB Lower31.84Neutral
- ATR0.36Low Volatility
- IndicatorValueSignal
- MFI42.03Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1033.56Bullish
- SMA 2034.71Bearish
- SMA 5036.09Bearish
- EMA 1033.86Bullish
- EMA 2034.60Bearish
- EMA 5036.60Bearish
- DEMA 1033.20Bullish
- DEMA 2033.29Bullish
- DEMA 50N/AN/A
- TEMA 1033.33Bullish
- TEMA 2033.08Bullish
- TEMA 50N/AN/A
- MACD-1.00Bearish
- ADX19.42Weak Trend
- IndicatorValueSignal
- RSI43.97Neutral
- CCI-48.53Neutral
- ROC 9-0.29Bearish
- ROC 14-3.14Bearish
- ROC 25-10.55Bearish
- Stoch K31.90Neutral
- Stoch D23.89Neutral
- IndicatorValueSignal
- BB Upper37.39Neutral
- BB Middle34.71Neutral
- BB Lower32.04Neutral
- ATR0.76Low Volatility
- IndicatorValueSignal
- MFI36.94Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1034.70Bearish
- SMA 2035.72Bearish
- SMA 5037.63Bearish
- SMA 10037.04Bearish
- SMA 20042.87Bearish
- EMA 1034.45Bearish
- EMA 2035.37Bearish
- EMA 5036.54Bearish
- EMA 10038.31Bearish
- EMA 20042.65Bearish
- DEMA 1033.33Bullish
- DEMA 2034.07Bearish
- DEMA 5035.10Bearish
- DEMA 10034.29Bearish
- DEMA 200N/AN/A
- TEMA 1032.99Bullish
- TEMA 2033.39Bullish
- TEMA 5035.23Bearish
- TEMA 10034.95Bearish
- TEMA 200N/AN/A
- MACD-1.04Bearish
- ADX10.59Weak Trend
- IndicatorValueSignal
- RSI44.16Neutral
- CCI-107.99Oversold
- ROC 14-4.51Bearish
- ROC 25-10.79Bearish
- Stoch K10.17Oversold
- Stoch D4.58Oversold
- IndicatorValueSignal
- BB Upper39.33Neutral
- BB Middle35.72Neutral
- BB Lower32.11Neutral
- ATR1.49Low Volatility
- IndicatorValueSignal
- MFI41.58Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 2036.19Bearish
- SMA 5040.14Bearish
- EMA 2036.76Bearish
- EMA 5040.21Bearish
- DEMA 2035.04Bearish
- DEMA 5034.16Bearish
- TEMA 2035.54Bearish
- TEMA 50N/AN/A
- MACD-1.25Bearish
- ADX35.17Strong Trend
- IndicatorValueSignal
- RSI43.46Neutral
- CCI-90.50Neutral
- ROC 14-15.34Bearish
- ROC 25-11.39Bearish
- Stoch K6.79Oversold
- Stoch D15.04Oversold
- IndicatorValueSignal
- BB Upper42.82Neutral
- BB Middle36.19Neutral
- BB Lower29.55Neutral
- ATR3.99Low Volatility
- IndicatorValueSignal
- MFI32.64Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 635.80Bearish
- SMA 1239.46Bearish
- SMA 2445.28Bearish
- EMA 636.80Bearish
- EMA 1239.55Bearish
- EMA 2445.27Bearish
- DEMA 634.80Bullish
- DEMA 1234.27Bullish
- DEMA 24N/AN/A
- TEMA 635.25Bearish
- TEMA 12N/AN/A
- TEMA 24N/AN/A
- MACDN/AN/A
- ADX17.66Weak Trend
- IndicatorValueSignal
- RSI37.13Neutral
- CCIN/AN/A
- ROC 25-44.17Bearish
- ROC 50N/AN/A
- Stoch KN/AN/A
- Stoch DN/AN/A
- IndicatorValueSignal
- BB Upper55.97Neutral
- BB Middle43.41Neutral
- BB Lower30.85Neutral
- ATR9.97Low Volatility
- IndicatorValueSignal
- MFI62.32Neutral